Test Price
2,800 AED✅ Home Collection Available
FXN Gene Friedreich Ataxia Genetic Test – NGS-Based Molecular Diagnosis in Dubai, UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available Daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for Result Interpretation by a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced next‑generation sequencing (NGS) test comprehensively analyzes the FXN gene for GAA trinucleotide repeat expansions and point mutations responsible for Friedreich ataxia—a progressive, autosomal recessive neurodegenerative disorder. The assay covers all coding exons and flanking intronic regions using Illumina® NGS technology with clinical-grade bioinformatics pipelines, providing definitive molecular diagnosis when interpreted alongside neurological examination and family history. Results are reported per ACMG guidelines with variant classification support.
| Feature | Our Test (FXN NGS) | Traditional PCR / Sanger |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity – detects full spectrum (repeat expansions, point variants) | Lower sensitivity; may miss rare point mutations |
| Methodology | Illumina® NGS with clinical-grade bioinformatics, aligned to current ACMG standards | Sanger sequencing / PCR fragment analysis |
| Turnaround Time | 3–4 weeks | 4–6 weeks (often with multi-step referrals) |
| DHA / MOHAP Compliance | Full DHA genetic testing standards, facility license 1143, Dubai Healthcare City | Varies; may require additional validation |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I recommend this NGS-based FXN gene analysis as the gold standard for confirming a diagnosis of Friedreich ataxia. The test provides comprehensive detection of both GAA repeat expansions and point mutations, which is essential for accurate genetic counseling, prognosis assessment, and family planning. I personally oversee the clinical interpretation of each result and am available to discuss findings with patients and referring physicians.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This test does not alter existing treatment regimens; continue all therapies as directed by your physician.
Exclusion Criteria & Safety Red Flags
Exclusion Criteria: This test requires informed consent; minors (under 18 years) strictly require legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability. Not indicated for asymptomatic individuals without a family history unless part of a formal genetic counseling program. Pre-test counseling is mandatory.
Urgent Red Flags: If you experience sudden loss of coordination, difficulty walking, slurred speech, or loss of consciousness, seek emergency medical evaluation immediately. This test is not a substitute for acute neurological care.
Patient FAQ & Clinical Guidance
1. What is the FXN Gene Friedreich Ataxia Genetic Test?
This test precisely identifies GAA trinucleotide repeat expansions and point mutations in the FXN gene using next-generation sequencing, enabling a definitive molecular diagnosis of Friedreich ataxia. It covers all coding regions with 99.9% diagnostic sensitivity, and results are interpreted per current ACMG guidelines for variant classification.
2. How long does it take to get results?
Turnaround time is 3 to 4 weeks after sample receipt. Results are delivered through our secure online portal with integrated clinical interpretation support by a DHA-licensed Consultant Medical Geneticist.
3. Is the test painful or dangerous?
No. The test requires a standard venous blood draw or a quick finger-prick onto an FTA card—both are minimally invasive and pose no significant risk when performed by our certified phlebotomist during home collection or at our Dubai Healthcare City facility.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: All genetic data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory operations are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). All genetic information is stored on UAE-based secure servers with role-based access controls, encryption at rest and in transit, and strict audit logging.
Clinical & Logistical Metadata
| Test Name | FXN Gene Friedreich Ataxia Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (Venous Draw or Finger-Prick FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina® Platform with Clinical-Grade Bioinformatics Analysis |
| ICD-10-CM Code | G11.1 |
| LOINC Code | 21779-6 |
| DHA Facility License & Laboratory Address | Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians